loading
Schlusskurs vom Vortag:
$31.01
Offen:
$30.96
24-Stunden-Volumen:
969.93K
Relative Volume:
0.81
Marktkapitalisierung:
$2.33B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-11.06
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
-4.08%
1M Leistung:
-4.60%
6M Leistung:
-24.16%
1J Leistung:
-30.90%
1-Tages-Spanne:
Value
$30.23
$31.39
1-Wochen-Bereich:
Value
$30.23
$32.32
52-Wochen-Spanne:
Value
$26.74
$46.00

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name
Firmenname
Xenon Pharmaceuticals Inc
Name
Telefon
(604) 484-3300
Name
Adresse
200 - 3650 GILMORE WAY, BURNABY
Name
Mitarbeiter
327
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
XENE's Discussions on Twitter

Vergleichen Sie XENE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
XENE
Xenon Pharmaceuticals Inc
30.30 2.38B 13.17M -199.06M -156.53M -2.74
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-07 Eingeleitet Chardan Capital Markets Buy
2025-02-11 Eingeleitet Deutsche Bank Buy
2024-10-10 Fortgesetzt Raymond James Outperform
2024-10-01 Eingeleitet H.C. Wainwright Buy
2024-01-04 Eingeleitet Citigroup Buy
2023-12-08 Eingeleitet Robert W. Baird Outperform
2023-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2023-04-25 Eingeleitet Cantor Fitzgerald Overweight
2022-12-14 Eingeleitet Goldman Buy
2022-12-12 Eingeleitet Cowen Outperform
2022-11-28 Eingeleitet Wells Fargo Overweight
2022-10-19 Eingeleitet Raymond James Outperform
2022-08-29 Eingeleitet BofA Securities Buy
2022-07-21 Eingeleitet JP Morgan Overweight
2021-10-28 Eingeleitet RBC Capital Mkts Outperform
2020-10-02 Eingeleitet SVB Leerink Outperform
2020-07-21 Eingeleitet Needham Buy
2020-06-01 Fortgesetzt Jefferies Buy
2020-03-25 Eingeleitet Wedbush Outperform
2020-01-08 Eingeleitet William Blair Outperform
2019-09-20 Eingeleitet Guggenheim Buy
2018-08-08 Bestätigt Stifel Buy
2017-03-13 Eingeleitet Jefferies Buy
2016-10-21 Eingeleitet Stifel Buy
2016-09-26 Eingeleitet Guggenheim Buy
2016-04-14 Bestätigt Jefferies Buy
2015-10-30 Fortgesetzt Jefferies Buy
2014-12-02 Eingeleitet Canaccord Genuity Buy
Alle ansehen

Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten

pulisher
Jul 25, 2025

What drives Xenon Pharmaceuticals Inc. stock priceMassive wealth growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Xenon Pharmaceuticals Inc. Stock Analysis and ForecastExceptional ROI - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about Xenon Pharmaceuticals Inc. stockExplosive trading opportunities - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World

Jul 24, 2025
pulisher
Jul 23, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Bank of New York Mellon Corp - Defense World

Jul 23, 2025
pulisher
Jul 22, 2025

How Xenon Pharmaceuticals Inc. stock performs during market volatilityFree Access to Community - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Is Xenon Pharmaceuticals Inc. a good long term investmentFree Stock Selection - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Mutual of America Capital Management LLC Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

Jul 21, 2025
pulisher
Jul 20, 2025

Should I buy Xenon Pharmaceuticals Inc. stock before earningsFree Smart Money Stock Analysis - Newser

Jul 20, 2025
pulisher
Jul 19, 2025

(XENE) Investment Analysis and Advice - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 16, 2025

Teacher Retirement System of Texas Reduces Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Why Xenon Pharmaceuticals Inc. stock attracts strong analyst attentionReliable High Profit Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Xenon Pharmaceuticals Inc. stock price move sharplyHigh Yield Opportunities - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely - Yahoo Finance

Jul 14, 2025
pulisher
Jul 10, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of “Buy” by Brokerages - Defense World

Jul 10, 2025
pulisher
Jul 10, 2025

Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World

Jul 10, 2025
pulisher
Jul 08, 2025

How to Take Advantage of moves in (XENE) - news.stocktradersdaily.com

Jul 08, 2025
pulisher
Jul 07, 2025

CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com

Jul 07, 2025
pulisher
Jul 06, 2025

RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN

Jul 06, 2025
pulisher
Jul 04, 2025

Xenon Appoints CEO Ian Mortimer as Interim CFO - The Globe and Mail

Jul 04, 2025
pulisher
Jul 03, 2025

XENE CEO Named Interim CFO After Sherry Aulin Resigns | XENE SEC FilingForm 8-K - Stock Titan

Jul 03, 2025
pulisher
Jun 30, 2025

Xenon Pharmaceuticals Inc.(NasdaqGM:XENE) added to Russell Small Cap Comp Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 29, 2025

Xenon Pharmaceuticals: Riding the Russell Wave to Institutional Inflows and Clinical Milestones? - AInvest

Jun 29, 2025
pulisher
Jun 28, 2025

Xenon Joins the Russell 3000® and Russell 2000® Indexes - The Manila Times

Jun 28, 2025
pulisher
Jun 27, 2025

Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes - Investing.com India

Jun 27, 2025
pulisher
Jun 27, 2025

Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - Quiver Quantitative

Jun 27, 2025
pulisher
Jun 27, 2025

Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes By Investing.com - Investing.com UK

Jun 27, 2025
pulisher
Jun 26, 2025

Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks

Jun 26, 2025
pulisher
Jun 25, 2025

Is Xenon Pharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025
pulisher
Jun 24, 2025

XENE: Xenon Pharmaceuticals Welcomes New Chief Commercial Officer | XENE Stock News - GuruFocus

Jun 24, 2025
pulisher
Jun 18, 2025

Long Term Trading Analysis for (XENE) - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 15, 2025

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $57 - 富途牛牛

Jun 14, 2025
pulisher
Jun 13, 2025

Xenon Pharmaceuticals price target raised to $57 from $55 at RBC Capital - Investing.com Canada

Jun 13, 2025

Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Xenon Pharmaceuticals Inc-Aktie (XENE) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
GANNON STEVEN
Director
May 14 '25
Option Exercise
12.57
5,144
64,660
7,144
MORTIMER IAN
PRESIDENT & CEO
Jan 24 '25
Option Exercise
17.76
22,468
399,032
53,770
MORTIMER IAN
PRESIDENT & CEO
Jan 27 '25
Option Exercise
17.76
16,315
289,754
46,468
MORTIMER IAN
PRESIDENT & CEO
Jan 23 '25
Option Exercise
17.76
16,217
288,014
47,519
MORTIMER IAN
PRESIDENT & CEO
Jan 24 '25
Sale
40.20
22,468
903,214
31,302
MORTIMER IAN
PRESIDENT & CEO
Jan 27 '25
Sale
40.50
16,315
660,806
31,302
MORTIMER IAN
PRESIDENT & CEO
Jan 23 '25
Sale
40.08
16,217
649,977
31,302
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):